These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20541584)

  • 21. Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson's disease.
    Chao YX; He BP; Tay SS
    J Neuroimmunol; 2009 Nov; 216(1-2):39-50. PubMed ID: 19819031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.
    Anglade P; Vyas S; Javoy-Agid F; Herrero MT; Michel PP; Marquez J; Mouatt-Prigent A; Ruberg M; Hirsch EC; Agid Y
    Histol Histopathol; 1997 Jan; 12(1):25-31. PubMed ID: 9046040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective response of various brain cell types during neurodegeneration induced by mild impairment of oxidative metabolism.
    Ke ZJ; Gibson GE
    Neurochem Int; 2004; 45(2-3):361-9. PubMed ID: 15145550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
    Testa CM; Sherer TB; Greenamyre JT
    Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does autophagy worsen or improve the survival of dopaminergic neurons?
    Pasquali L; Ruggieri S; Murri L; Paparelli A; Fornai F
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S24-7. PubMed ID: 20123552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium ions in neuronal degeneration.
    Wojda U; Salinska E; Kuznicki J
    IUBMB Life; 2008 Sep; 60(9):575-90. PubMed ID: 18478527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia.
    Trojanowski JQ; Goedert M; Iwatsubo T; Lee VM
    Cell Death Differ; 1998 Oct; 5(10):832-7. PubMed ID: 10203692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regional vulnerability of mesencephalic dopaminergic neurons prone to degenerate in Parkinson's disease: a post-mortem study in human control subjects.
    Lu L; Neff F; Fischer DA; Henze C; Hirsch EC; Oertel WH; Schlegel J; Hartmann A
    Neurobiol Dis; 2006 Aug; 23(2):409-21. PubMed ID: 16753304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of donor age and brain-derived neurotrophic factor on the survival of dopaminergic neurons and axonal growth in postnatal rat nigrostriatal cocultures.
    Ostergaard K; Jones SA; Hyman C; Zimmer J
    Exp Neurol; 1996 Dec; 142(2):340-50. PubMed ID: 8934565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Degeneration of dopaminergic neurons in the substantia nigra of zitter mutant rat and protection by chronic intake of Vitamin E.
    Ueda S; Sakakibara S; Nakadate K; Noda T; Shinoda M; Joyce JN
    Neurosci Lett; 2005 Jun; 380(3):252-6. PubMed ID: 15862896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrastriatal infusions of brain-derived neurotrophic factor: retrograde transport and colocalization with dopamine containing substantia nigra neurons in rat.
    Mufson EJ; Kroin JS; Sobreviela T; Burke MA; Kordower JH; Penn RD; Miller JA
    Exp Neurol; 1994 Sep; 129(1):15-26. PubMed ID: 7523178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration.
    Saxena S; Caroni P
    Neuron; 2011 Jul; 71(1):35-48. PubMed ID: 21745636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update.
    Brichta L; Greengard P
    Front Neuroanat; 2014; 8():152. PubMed ID: 25565977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Live-cell imaging in the study of neurodegeneration.
    Bakota L; Brandt R
    Int Rev Cell Mol Biol; 2009; 276():49-103. PubMed ID: 19584011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence That Substantia Nigra Pars Compacta Dopaminergic Neurons Are Selectively Vulnerable to Oxidative Stress Because They Are Highly Metabolically Active.
    Ni A; Ernst C
    Front Cell Neurosci; 2022; 16():826193. PubMed ID: 35308118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The interrelations between malfunctioning DNA damage response (DDR) and the functionality of the neuro-glio-vascular unit.
    Barzilai A
    DNA Repair (Amst); 2013 Aug; 12(8):543-57. PubMed ID: 23706773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Neuronal ageing].
    Piechota M; Sunderland P
    Postepy Biochem; 2014; 60(2):177-86. PubMed ID: 25134353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneity of dopamine release sites in health and degeneration.
    Lebowitz JJ; Khoshbouei H
    Neurobiol Dis; 2020 Feb; 134():104633. PubMed ID: 31698055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.